To determine prevalence and patterns of use of complementary and alternative medicine (CAM) among men recently diagnosed with prostate cancer. Study Design: Men, diagnosed with prostate cancer over a 10-month period in British Columbia, Canada, were randomly selected to obtain a population-based sample. Methods: Surveys, addressing patient demographics, types of CAM therapies, and CAM information resources utilized, reasons for use, and disclosure to physician(s), were mailed to 1108 men newly diagnosed with prostate cancer. A 42% response rate was obtained. Results: Thirty-nine percent of patients used CAM therapies with the most common being herbal supplements (saw palmetto), vitamins (vitamin E), and minerals (selenium). The most common reasons given for choosing to use CAM therapies were to (1) boost the immune system and (2) prevent recurrence. The majority of men (58%) had told their physician(s) about their CAM use, but few utilized either their family physician (15%) or their oncologist (7%) as sources of CAM information. CAM users most commonly consulted friends or family (39%) or the Internet (19%) for information about CAM. CAM users were more likely than nonusers to delay (9%) or decline (4%) conventional treatment. Respondents who had never used CAM had typically never thought about it or did not have enough information about the treatments. Conclusions: More than one third of recently diagnosed prostate cancer patients utilize some form of CAM therapy, and the majority disclose their use to their physician(s). However, they tend to rely on anecdotal information for their CAM decision making. Dissemination of reliable CAM information is one key to helping men navigate this difficult arena.
There has been discussion in literature around what constitutes complementary and alternative medicine (CAM). 1, 2 Some practitioners and researchers include common practices like exercise or eating a low-fat diet within the CAM definition, whereas others would argue these are conventional approaches to health care. The lack of a standard definition and a decisive list of CAM therapies and products is just one of the issues that have hindered research in the field of CAM. For the purposes of this study, CAM has been defined as an approach to diagnosis, treatment, and care that falls outside of conventional therapies widely used in North America. 3 This definition used here is broad and includes a wide array of treatments under the CAM umbrella.
Canadians continue to utilize complementary and alternative therapies at a growing rate, with current research estimating that as many as 1 in every 2 Canadians are taking an integrated approach to their health, having used or are currently using some form of CAM therapy or product in addition to their conventional medical care. 4 Those living with chronic illnesses such as cancer are one of the largest segments of the population to utilize CAM therapies. The prevalence of CAM use, in 26 studies that examined a variety of cancers, ranged from 7% to 64%, with an average prevalence of 31.4% across 13 countries. 5 Little is known about CAM utilization in men diagnosed with prostate cancer. Although some crosssectional studies have been conducted, these have been limited by small sample sizes or convenience samples, where men from small or distinct populations such as clinical settings were asked to participate. [6] [7] [8] [9] Thus, these studies are not population based, and hence their findings are restricted in their generalizability. Individuals who are potentially missing in these samples include those undergoing watchful-waiting and those who decline conventional mainstream treatment. Despite their limitations, studies estimate that CAM use ranges from 16.5% to 37% among men attending cancer treatment centers, [6] [7] [8] [9] up to 62% of men attending support groups. 10 A wide range of CAM therapies, touted in the popular media as beneficial for treating or preventing prostate cancer, have been described without highlighting the range of toxicities that might be associated with their use. 11 An additional concern is the potential for patients to unwittingly utilize CAM therapies (eg, antioxidants), which interact with their conventional treatments (eg, radiotherapy), or affect biological markers (eg, PSA) that are relevant to treatment decisions. Studies have shown that cancer patients are hesitant to inform their physicians of their CAM use, with an estimated 40% of patients choosing not to do so. 12 Given the lack of population-based data on CAM use in prostate cancer patients and the potential harmful side effects that may be associated with some CAM therapies, we conducted a population-based survey of CAM use in newly diagnosed prostate cancer patients. Specific areas of investigation were prevalence and types of therapies used, reasons for use, prior experience with CAM, and the information resources utilized in choosing specific CAM therapies.
Methods
The Behavioural Ethics Committee of the University of British Columbia and the Clinical Investigations Committee of the British Columbia Cancer Agency approved the protocol for this study. The British Columbia Cancer Agency is responsible for registering all newly diagnosed cancer cases in the Province of BC. The registry has been in operation since 1969, and ascertainment is more than 98% complete. Men newly diagnosed with prostate cancer were identified through consecutive registrations on the cancer registry between January 1, 2000, and October 31, 2000. Men 80 years of age and older at time of diagnosis were excluded from the sample. There were 2033 men under the age of 80 registered with prostate cancer during this time frame. Based on a projected response rate of 50% and estimates for the population based on the sample of ± 4% accuracy with 95% confidence, a random sample of 1341 names was required. 13 Seventy of these patients were dropped from the sample because their mailing addresses were unavailable at the time of the survey, leaving a sample of 1271.
To ensure that the 1271 men selected for the sample had been made aware of their diagnosis, each participant's family physician was contacted by letter and asked to fill out a reply form and return it via mail or fax. Physicians who had more than 1 patient in the sample were asked to complete a form for each patient. In instances where the family physician could not be contacted (ie, physician had moved offices), the urologist was contacted.
Upon physician confirmation that patients were aware of their prostate cancer diagnosis, a package was mailed to each participant consisting of a 1-page cover letter explaining the purpose of the study, a 9-page survey, and a postage-paid self-addressed envelope. The survey was developed specifically for prostate cancer patients and included items from questionnaires previously developed by one of the researchers (MV) to examine alternative therapy use in other disease groups. The survey was made up of 19 questions, requesting demographic information, diagnostic and conventional treatments received, specific CAM therapies used, reasons for use and perceived benefit, disclosure to physician(s), and utilization of CAM information resources.
All data were entered into SPSS 10.0 14 and analyzed primarily for descriptives including frequencies and summary measures. Chi-square analysis was used to test differences between variables as needed.
Results
Ninety-one percent (n = 1162) of physicians completed and returned the reply form as requested. Physicians indicated that 1108 patients were aware of their prostate cancer diagnosis, whereas only 16 patients were unaware. Physicians most often specified dementia or another cognitive impairment as the reason that their patient was unaware. An additional 38 patients were determined to be unable to participate because their physicians indicated that they were too ill or had died (n = 16), the physician or patient was unwilling (n = 10), the patient did not have prostate cancer (n = 7), or the physician had no contact with the patient (n = 5).
Based on physician responses, surveys were sent to the 1108 participants who were known to be aware of their prostate cancer diagnosis. Of these, 28 participants had moved with no forwarding address and 1 patient refused delivery. Of the 1079 surveys delivered, 451 (42%) were completed and returned.
At the time of responding to the survey, the men ranged in age from 47 to 81 years, with an average age of 68 years (SD = 7.5). The majority of men were born in Canada (67%), had completed high school or beyond (80%), were married (81%), and had retired from their jobs (76%). When asked which ethnic group they most identified with, 92% indicated Caucasian, 4% indicated Asian, and 4% indicated 1 of 4 other ethnic categories. Upon receipt of the survey, the average amount of time that had passed since their prostate cancer diagnosis was 13 months (SD = 3.9).
Conventional medical treatment had been or was being received by 99% of the men (Table 1) , with the majority undergoing radiation or radical prostatectomy, most in combination with hormone therapy. Use of CAM therapies was prevalent among this group. Of the 451 participants, 175 (39%) reported using CAM treatments. Of these, 30% began use after their prostate cancer diagnosis. Chi-square analysis showed no significant links between CAM use and demographic variables, which included age, education, marital status, and employment status.
Fifty-eight percent of respondents reported telling their doctor(s) about their CAM use, whereas 13% had not, and 29% chose not to respond to this question. For those who responded, only 28% indicated that their doctors had asked them about CAM. All participants who chose not to tell their doctor(s) reported that their doctor did not ask. When asked about doctor responses to their disclosure, 27% reported a positive reaction, 10% reported a negative reaction, 36% reported a neutral reaction, and 27% reported a mixed reaction.
A number of respondents (n = 40) reported delaying medical treatment recommended by their doctor, and 17 reported declining one or more conventional treatments offered. Of these, 3 had declined all forms of conventional treatment. It was anticipated that there would be a relationship between CAM users and those who delayed or declined conventional treatments. Chi-square analysis supported this hypothesis (χ 2 = 23.3, df = 3, P ≤ .0001). The most common therapy to be delayed or declined was radiation (n = 34), followed by prostatectomy (n = 22), hormone therapy (n = 15), orchiectomy (n = 4), and brachytherapy (n = 2). Some participants indicated they had delayed or declined more than one type of treatment (range = 1-4).
Respondents gave a variety of reasons for using CAM therapies ( Table 2 ). Boosting the immune system and preventing recurrence were the leading reasons, with most participants indicating more than one reason for using CAM.
The men in our sample used numerous CAM therapies. Therapies under the categories of herbal supplements, vitamins, and minerals were selected most often. Of the 95 therapies listed on the survey, participants indicated they had used 71 of them. Furthermore, respondents listed a wide variety of additional therapies under the category of "other." Therapies represented 10 different areas of CAM practice (Table  3 ). Seventy-one percent of respondents combined treatments from 2 or more practices (mean number of categories = 2.9, SD = 1.95, range = 1-10).
Respondents, who had utilized CAM therapies to treat their prostate cancer, were asked to indicate on a 5-point scale how they perceived these therapies to have affected their disease. More than half (60%) of respondents felt they were better or a lot better on measures of energy level, stress, sense of control over disease, and PSA levels. The remainder felt their use of CAM therapies had had no effect on these measures, and a few reported they were worse off in these areas (4%, 3%, 5%, and 1%, respectively). In contrast, when asked if their use of CAM therapies had helped in minimizing the side effects of conventional treatments, only one third (34%) reported their side effects were better or a lot better, 56% reported no effect, and 10% reported they felt the CAM treatments had made their side effects worse or a lot worse.
The men in the sample utilized a number of resources to obtain information on CAM (Table 4) , with the most common resources being friends or relatives (39%), followed by the Internet (19%) .
When asked if they had ever used any form of CAM therapies, 61% of men indicated they had not. The most common reasons given for not having used CAM a. Some respondents have undergone more than one type of conventional treatment and therefore the total does not equal 100%. were (1) never thought about it and (2) did not have enough information about treatments. Table 5 lists all the reasons and the frequency of responses given. Most men indicated more than one reason for choosing not to use CAM.
Discussion
Although the response rate for this study is somewhat low (42%), the sample does appear to be representative of men with prostate cancer in the province of British Columbia. The average age of the respondents in this study (68 years) is similar to that of nonrespondents (67 years). Furthermore, the ethnic background (92% Caucasian) of respondents is similar to that of all men diagnosed with prostate cancer in BC in the last 10 years (95.2%). 15 The less than optimal response rate for this study may be attributed, at least in part, to the type of population sampled. Most studies assessing CAM use have used clinical samples, 16 which tend to have a much higher response rate than community-based samples. In addition, to protect subject anonymity, no follow-up was carried out.
In this study, 39% of men reported they had used CAM therapies, either to treat their prostate cancer or before their cancer diagnosis. This number is high compared to similar studies, [6] [7] [8] [9] which also examined CAM use among prostate cancer patients. These differences may be a reflection of the geographic locations from which the samples were drawn, the definition of CAM used in each of the studies, and the kinds of populations from which the samples were drawn (treatment centers vs community wide).
In this study, the leading reasons men gave for using CAM therapies were to boost the immune system and to prevent recurrence. Interestingly, only 21% of men were using CAM to try to cure their prostate disease, contradicting the widely held belief that patients are turning to CAM to find that "magic bullet." In comparison, a study by Wilkinson et al 8 found that the majority of men used CAM to help them live longer (90%) and improve their quality of life (60%). However, 47% of this group expected CAM therapies to cure their disease.
Men reported herbals, vitamins, and minerals as the most commonly used therapies. Of these, saw palmetto, vitamin E, and selenium were selected most frequently to treat prostate cancer. Interestingly, a similar study of alternative medicine use among men with prostate cancer in the United Kingdom 9 found that tomatoes, tomato-based products, and a low-fat diet were utilized most frequently. This may be a reflection of differences in public consciousness between countries around which CAM therapies are most effective. It may also be a result of the availability of specific CAM therapies.
There is some evidence that each of saw palmetto, vitamin E, and selenium provides some benefit for the prevention and/or treatment of prostate cancer. Saw palmetto, derived from the saw palm tree, has been widely used in Europe and is gaining ground in North America. Some studies have shown it to be effective in shrinking the prostate and curbing prostate cell growth in vitro. 17 A randomized trial conducted in Finland suggested that vitamin E might afford modest protection against prostate cancer; however, this was a secondary study endpoint and needs further confirmation. 18 The metallic element selenium found in meat, nuts, cruciferous vegetables, seafood, and wheat is also thought to act as an antioxidant, which promotes cancer cell death. 19 Currently, clinical trials are under way to further evaluate the mechanisms by which selenium might work. One of the largest CAM multicenter prevention studies ever conducted was launched in 2000 and is a randomized crossover study designed to investigate the effects of selenium, vitamin E, and the combination of the two on the incidence of prostate cancer in North America. 20 Although there is some evidence to support the use of these products in treating prostate disease, the sources of information accessed by patients to aid in their decision making around CAM use is primarily anecdotal. When men were asked where they obtained information about CAM therapies, the most common response was friends and family (39%), followed by the Internet (19%). Whereas most CAM users told their doctor, only 15% utilized their physician and 7% their oncologist as a source of information about CAM.
Conclusions
More than one third of prostate cancer patients in British Columbia are using a variety of CAM therapies for treatment and prevention. This study highlights the need for the expansion of the evidence base in the field of CAM so that patients may base their CAM treatment decisions on solid evidence. The impact of CAM therapies on patients' overall quality of life (energy level, control of side effects) should also be considered in future research.
